+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chagas Disease (American Trypanosomiasis) - Pipeline Review, H1 2020

  • ID: 5024734
  • Drug Pipelines
  • April 2020
  • Region: United States
  • 92 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AstraZeneca Plc
  • Cesa Alliance SA
  • Diakonos Research Ltd
  • Evotec SE
  • IC-MedTech Inc
  • Oblita Therapeutics BVBA
  • MORE
Chagas Disease (American Trypanosomiasis) - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Chagas Disease - Pipeline Review, H1 2020, provides an overview of the Chagas Disease (Infectious Disease) pipeline landscape.

Chagas disease or American Trypanosomiasis is a vector-borne anthropozoonosis caused by the protozoan parasite Trypanosoma cruzi. Symptoms include swelling at the infection site, fever, fatigue, body aches, loss of appetite, nausea, diarrhea or vomiting and swollen glands. Treatment includes antiparasitic medications.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chagas Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chagas Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Preclinical, Discovery and Unknown stages are 1, 3, 6, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 18 and 5 molecules, respectively.

Chagas Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chagas Disease (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Chagas Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chagas Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chagas Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chagas Disease (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chagas Disease (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chagas Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca Plc
  • Cesa Alliance SA
  • Diakonos Research Ltd
  • Evotec SE
  • IC-MedTech Inc
  • Oblita Therapeutics BVBA
  • MORE
  • Introduction
  • Report Coverage
  • Chagas Disease (American Trypanosomiasis) - Overview
  • Chagas Disease (American Trypanosomiasis) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Chagas Disease (American Trypanosomiasis) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Chagas Disease (American Trypanosomiasis) - Companies Involved in Therapeutics Development
  • AstraZeneca Plc
  • Bayer AG
  • Cesa Alliance SA
  • Collaborations Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • Diakonos Research Ltd
  • Eisai Co Ltd
  • Evotec SE
  • GlaxoSmithKline Plc
  • Grupo Praxis Pharmaceutical SA
  • IC-MedTech Inc
  • Novartis AG
  • Oblita Therapeutics BVBA
  • Sanofi
  • Synstar Japan Co Ltd
  • Chagas Disease (American Trypanosomiasis) - Drug Profiles
  • (sodium ascorbate + menadione sodium bisulfite) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AP-3 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • benznidazole - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • chagas disease (bivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • chagas disease vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Chagas disease vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Chagas disease vaccine 2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cz-007 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cz-008 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • D-121 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DNDI-0690 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EPLBS-1246 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EPLBS-967 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fexinidazole - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fosravuconazole - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GNF-6702 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • K-777 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MAO-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nifurtimox - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pyronaridine tetraphosphate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SAR-114137 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule for Chagas Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule for Chagas Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Chagas Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Chagas Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Chagas Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Chagas Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Chagas Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Infectious Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Leishmaniasis and Chagas Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Protozoal Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Cruzipain for Chagas Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Cruzipain for Chagas Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit CYP51A1 for Chagas Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for African Trypanosomiasis, Chagas Disease and Leishmaniasis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Pex14 for Chagas Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Proline Racemase for Chagas Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VNI - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Chagas Disease (American Trypanosomiasis) - Dormant Projects
  • Chagas Disease (American Trypanosomiasis) - Discontinued Products
  • Chagas Disease (American Trypanosomiasis) - Product Development Milestones
  • Featured News & Press Releases
  • Jan 30, 2020: Bayer application for nifurtimox to treat pediatric patients with Chagas disease submitted for approval in US
  • Mar 14, 2019: Phase III clinical trial with Bayer's nifurtimox demonstrates safety and efficacy of new formulation to treat children with Chagas disease
  • Jun 22, 2017: UTEP Scientists Awarded Patent for Chagas Disease Vaccine
  • Nov 15, 2016: Bayer to Fight Chagas Disease in Children
  • Aug 08, 2016: A single compound could treat three parasitic diseases
  • Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease
  • Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease
  • Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy
  • May 03, 2013: Funding boost for GSK’s open innovation research into diseases affecting the developing world
  • Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease
  • Mar 12, 2012: DNDi Receives €2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Chagas Disease (American Trypanosomiasis), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by AstraZeneca Plc, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Bayer AG, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Cesa Alliance SA, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Collaborations Pharmaceuticals Inc, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Diakonos Research Ltd, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Eisai Co Ltd, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Evotec SE, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Grupo Praxis Pharmaceutical SA, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by IC-MedTech Inc, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Novartis AG, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Oblita Therapeutics BVBA, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Sanofi, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Pipeline by Synstar Japan Co Ltd, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Dormant Projects, H1 2020
  • Chagas Disease (American Trypanosomiasis) - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Chagas Disease (American Trypanosomiasis), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AstraZeneca Plc
  • Bayer AG
  • Cesa Alliance SA
  • Collaborations Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • Diakonos Research Ltd
  • Eisai Co Ltd
  • Evotec SE
  • GlaxoSmithKline Plc
  • Grupo Praxis Pharmaceutical SA
  • IC-MedTech Inc
  • Novartis AG
  • Oblita Therapeutics BVBA
  • Sanofi
  • Synstar Japan Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll